THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Friday, November 20, 2026
A drug discovery platform can process thousands of compounds and still leave a program with weak evidence about what will matter in patients. Throughput is useful only when the biological readout has enough disease relevance to justify the next experiment. For executives, model choice deserves close scrutiny. A system built around a narrowly defined target may move quickly yet miss compounds that improve a disease phenotype through mechanisms that are incomplete or not fully understood. Phenotypic screening can widen the search, but only if the model produces measurable effects at a pace suitable for disciplined screening. The practical comparison is between volume and interpretability. A fast assay that generates ambiguous hits can create more downstream work, while a slower but biologically coherent screen may reduce expensive follow-up.
The next concern is how hits move from initial detection into a more credible development path. A useful platform should make that progression visible. Primary screening needs a clear readout, while secondary screening should test whether an observed effect holds under another biologically relevant condition. Structure-activity work then becomes more valuable because compound changes can be judged against an established phenotype rather than computational preference alone. Executives should look for a process that can reject weak candidates early and still preserve promising chemistry for further refinement. The handoff matters when a program moves from screening into preclinical work. Poorly connected stages can leave teams repeating experiments because the basis for advancing a compound was never clear enough.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
“Gilga-Med’s structure-activity work uses AI to predict and generate new small molecules from experimental data produced by the platform, keeping computation tied to measured biological effects.”
Small-molecule discovery also raises a different tradeoff around specificity. Compounds that affect more than one pathway can create side-effect risk, yet diseases involving aging or proteotoxic stress may not reduce neatly to a single molecular target. The better question is whether the platform can distinguish useful multi-pathway activity from uncontrolled pharmacology. Evidence should show that structural features can be adjusted while the desired biological effect is retained. A discovery system that supports iterative chemistry around observed function gives development teams more room to manage that tradeoff.
Artificial intelligence adds little when it is detached from proprietary experimental data. Its practical use increases when models are trained on repeated structure-activity relationships tied to measured phenotypes. That connection matters because prediction should shorten the next design cycle, not merely produce more candidate structures. Executives should examine how experimental results feed back into compound generation and whether each round creates information that sharpens the following one. The strongest platforms treat computation as part of a closed discovery loop rather than a substitute for biological testing. Long-term advantage comes from accumulating experimentally grounded relationships that make future predictions more specific to the platform’s own chemistry.
Gilga-Med uses high-throughput phenotypic screening in C. elegans disease models to identify small molecules based on observed biological effects rather than a predefined target. Its discovery process starts with primary screening and uses secondary assays to test promising hits. Structure-activity refinement follows. Its structure-activity work uses AI to predict and generate new small molecules from experimental data produced by the platform, keeping computation tied to measured biological effects. The same process produced GM310, which advanced into a mouse model of hemorrhagic stroke after earlier screening work. Gilga-Med is most relevant to buyers that favor phenotype-led discovery when target biology remains uncertain. For programs built around that scientific premise, it merits serious consideration.
More in News